Skip to main
QURE

uniQure (QURE) Stock Forecast & Price Target

uniQure (QURE) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 45%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

uniQure is a gene therapy company focused on developing treatments for genetic and other devastating diseases, with a strong pipeline and promising collaborations. The company has shown a focus on sustainability and growth while addressing high-cost and high-mortality diseases, which could position QURE for long-term success. However, as with any biotech company, there are inherent risks and uncertainties involved, and further clinical data and regulatory approvals are needed to fully support its potential for success.

Bears say

uniQure is heavily dependent on the success of its lead development candidate, AMT-130, for Huntington's disease, which has faced delays and setbacks in its development. Additionally, the company has a limited track record in the market, with no revenue-generating products currently. Their financials also pose risks, as they are a clinical stage company with high expenses and a reliance on grants and additional funding. The success of their pipeline and achievement of their target price is heavily dependent on the success and commercialization of AMT-130, making it a high-risk investment.

uniQure (QURE) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 45% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About uniQure (QURE) Forecast

Analysts have given uniQure (QURE) a Buy based on their latest research and market trends.

According to 11 analysts, uniQure (QURE) has a Buy consensus rating as of Jun 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

uniQure (QURE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.